Barclays (LON:BARC) analyst Gena Wang maintained a Buy rating on Alnylam Pharmaceuticals on Thursday, setting a price target of $210, which is approximately 31.61% above the present share price of $159.56.
Wang expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$1.61 for the fourth quarter of 2021.
The current consensus among 17 TipRanks analysts is for a Moderate Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $196.18.
The analysts price targets range from a high of $275 to a low of $108.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $220.55 million and a net profit of -$146.16 million. The company's market cap is $18.96 billion.
According to TipRanks.com, Barclays analyst Gena Wang is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.8% and a 48.85% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.